BRANCACCIO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.878
EU - Europa 563
AS - Asia 546
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
OC - Oceania 1
Totale 5.998
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.875
CN - Cina 298
IT - Italia 193
SG - Singapore 183
GB - Regno Unito 118
FI - Finlandia 61
FR - Francia 59
VN - Vietnam 49
DE - Germania 34
SE - Svezia 27
NL - Olanda 17
IE - Irlanda 15
UA - Ucraina 15
IN - India 13
RO - Romania 5
RS - Serbia 4
CA - Canada 3
ES - Italia 3
ET - Etiopia 3
MK - Macedonia 3
CH - Svizzera 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
HK - Hong Kong 2
PL - Polonia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BG - Bulgaria 1
BR - Brasile 1
NZ - Nuova Zelanda 1
PE - Perù 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.998
Salva come PNG Salva come JPEG
Città #
Fairfield 1.148
Woodbridge 461
Ashburn 446
Seattle 427
Houston 423
Cambridge 375
Wilmington 297
Chandler 220
Ann Arbor 198
Singapore 132
San Diego 126
Medford 85
Princeton 85
Beijing 76
Des Moines 67
Helsinki 57
Dong Ket 49
Nanjing 41
Padova 41
Santa Clara 27
Roxbury 26
Bareggio 19
Shenyang 19
Boardman 18
Dublin 15
Amsterdam 14
Guangzhou 14
Nanchang 13
Ogden 13
Zhengzhou 13
Kharkiv 12
Hebei 11
Jinan 10
Ningbo 9
Bagnaria Arsa 8
Bologna 7
Frankfurt am Main 7
Selvazzano Dentro 7
Borås 6
Teramo 6
Brescia 5
Changsha 5
London 5
Milan 5
Tianjin 5
Bari 4
Jiaxing 4
Kilburn 4
New York 4
Pune 4
Redmond 4
Rockville 4
Udine 4
Addis Ababa 3
Dallas 3
Haikou 3
Lappeenranta 3
Las Vegas 3
Norwalk 3
Rome 3
Skopje 3
Taiyuan 3
Acton 2
Agordo 2
Baselga di Pinè 2
Berlin 2
Camerino 2
Cesiomaggiore 2
Chennai 2
Chiswick 2
Foggia 2
Genoa 2
Hong Kong 2
Horia 2
Kanniyākumāri 2
Kunming 2
Los Angeles 2
Naples 2
New Bedfont 2
Ostra 2
Paris 2
Pontedera 2
Porto Garibaldi 2
Redwood City 2
San Fernando 2
Shanghai 2
Strasbourg 2
Taizhou 2
Washington 2
Zagazig 2
Berkeley 1
Bratislava 1
Clearwater 1
Esslingen am Neckar 1
Este 1
Falkenstein 1
Fano 1
Ferentino 1
Ferrara 1
Fontanelle 1
Totale 5.178
Salva come PNG Salva come JPEG
Nome #
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays 208
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 135
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 129
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 119
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 115
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 113
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 112
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 110
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 109
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 108
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 108
AISF position paper on HCV in immunocompromised patients 106
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 105
Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review 104
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 102
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 102
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis 96
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 95
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 95
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 89
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 89
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 88
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 87
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 84
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 83
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 83
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 82
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 81
Hepatitis c late relapse in patients with directly acting antiviral- related sustained virological response at week 12 81
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 80
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy 75
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 75
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 74
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 73
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 73
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues 70
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 70
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 70
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 70
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 69
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 69
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 68
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 67
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 66
Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study 66
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency 66
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 65
Hepatitis C Virus Clearance in Older Adults 64
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years 62
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 62
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 62
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 61
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 60
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 60
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 59
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 59
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 58
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 57
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 57
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 56
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 54
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 52
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 52
Liver transplantation for t2 hepatocellular carcinoma during the covid-19 pandemic: A novel model balancing individual benefit against healthcare resources 49
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 48
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 48
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 43
Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection 43
Hepatitis delta infection in Italian patients: towards the end of the story? 42
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 41
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 36
CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis 36
Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants 35
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 35
Letter Comment to: Which saint to pray for fighting against COVID? A short survey. By Perciaccante A et al. 31
Prophylaxis of hepatitis B virus (HBV) re-infection in liver transplantation: Is the reappearance of hepatitis B surface antigen (HBsAg) significant? 29
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 28
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 27
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 27
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply 26
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 25
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 23
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 23
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare 23
An increase in the levels of middle surface antigen characterizes patients developing hbv-driven liver cancer despite prolonged virological suppression 23
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 22
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 19
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 17
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 16
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 14
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma 10
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy 10
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 9
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 9
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 7
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 7
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 6
Recent breakthroughs in the treatment of chronic hepatitis Delta 6
Predicting de‐novo portal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort 5
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 5
Totale 6.122
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.293
article - articoli 23.911
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.356 0 0 0 190 189 146 160 181 239 121 76 54
2020/20211.081 45 69 49 47 167 59 57 107 154 47 189 91
2021/20221.290 78 175 145 73 68 63 90 136 90 32 110 230
2022/2023609 158 46 35 56 101 59 11 37 71 2 27 6
2023/2024488 16 63 41 68 42 35 52 16 33 15 41 66
2024/2025264 8 138 64 54 0 0 0 0 0 0 0 0
Totale 6.128